135 related articles for article (PubMed ID: 37351993)
1. Somatic and Germline Variants Affect Prognosis and Susceptibility in Prostate Cancer.
Rocca C; Rocca G; Zampieri P; Dell'atti L; Bianchi N; Ippolito C; Aguiari G
Anticancer Res; 2023 Jul; 43(7):2941-2949. PubMed ID: 37351993
[TBL] [Abstract][Full Text] [Related]
2. Detection of disease-causing mutations in prostate cancer by NGS sequencing.
Mangolini A; Rocca C; Bassi C; Ippolito C; Negrini M; Dell'Atti L; Lanza G; Gafà R; Bianchi N; Pinton P; Aguiari G
Cell Biol Int; 2022 Jul; 46(7):1047-1061. PubMed ID: 35347810
[TBL] [Abstract][Full Text] [Related]
3. Development of a Whole-urine, Multiplexed, Next-generation RNA-sequencing Assay for Early Detection of Aggressive Prostate Cancer.
Cani AK; Hu K; Liu CJ; Siddiqui J; Zheng Y; Han S; Nallandhighal S; Hovelson DH; Xiao L; Pham T; Eyrich NW; Zheng H; Vince R; Tosoian JJ; Palapattu GS; Morgan TM; Wei JT; Udager AM; Chinnaiyan AM; Tomlins SA; Salami SS
Eur Urol Oncol; 2022 Aug; 5(4):430-439. PubMed ID: 33812851
[TBL] [Abstract][Full Text] [Related]
4. Germline Mutations in ATM and BRCA1/2 Distinguish Risk for Lethal and Indolent Prostate Cancer and are Associated with Early Age at Death.
Na R; Zheng SL; Han M; Yu H; Jiang D; Shah S; Ewing CM; Zhang L; Novakovic K; Petkewicz J; Gulukota K; Helseth DL; Quinn M; Humphries E; Wiley KE; Isaacs SD; Wu Y; Liu X; Zhang N; Wang CH; Khandekar J; Hulick PJ; Shevrin DH; Cooney KA; Shen Z; Partin AW; Carter HB; Carducci MA; Eisenberger MA; Denmeade SR; McGuire M; Walsh PC; Helfand BT; Brendler CB; Ding Q; Xu J; Isaacs WB
Eur Urol; 2017 May; 71(5):740-747. PubMed ID: 27989354
[TBL] [Abstract][Full Text] [Related]
5. Mutations in ATM, NBN and BRCA2 predispose to aggressive prostate cancer in Poland.
Wokołorczyk D; Kluźniak W; Huzarski T; Gronwald J; Szymiczek A; Rusak B; Stempa K; Gliniewicz K; Kashyap A; Morawska S; Dębniak T; Jakubowska A; Szwiec M; Domagała P; Lubiński J; Narod SA; Akbari MR; Cybulski C;
Int J Cancer; 2020 Nov; 147(10):2793-2800. PubMed ID: 32875559
[TBL] [Abstract][Full Text] [Related]
6. Germline genetic variants in men with prostate cancer and one or more additional cancers.
Pilié PG; Johnson AM; Hanson KL; Dayno ME; Kapron AL; Stoffel EM; Cooney KA
Cancer; 2017 Oct; 123(20):3925-3932. PubMed ID: 28657667
[TBL] [Abstract][Full Text] [Related]
7. Gene-based Confirmatory Germline Testing Following Tumor-only Sequencing of Prostate Cancer.
Truong H; Breen K; Nandakumar S; Sjoberg DD; Kemel Y; Mehta N; Lenis AT; Reisz PA; Carruthers J; Benfante N; Joseph V; Khurram A; Gopalan A; Fine SW; Reuter VE; Vickers AJ; Birsoy O; Liu Y; Walsh M; Latham A; Mandelker D; Stadler ZK; Pietzak E; Ehdaie B; Touijer KA; Laudone VP; Slovin SF; Autio KA; Danila DC; Rathkopf DE; Eastham JA; Chen Y; Morris MJ; Offit K; Solit DB; Scher HI; Abida W; Robson ME; Carlo MI
Eur Urol; 2023 Jan; 83(1):29-38. PubMed ID: 36115772
[TBL] [Abstract][Full Text] [Related]
8. Metastatic prostate cancer is associated with distinct higher frequency of genetic mutations at diagnosis.
Al-Toubat M; Serrano S; Elshafei A; Koul K; Feibus AH; Balaji KC
Urol Oncol; 2023 Nov; 41(11):455.e7-455.e15. PubMed ID: 37838503
[TBL] [Abstract][Full Text] [Related]
9. SPOP and CHD1 alterations in prostate cancer: Relationship with PTEN loss, tumor grade, perineural infiltration, and PSA recurrence.
Hernández-Llodrà S; Segalés L; Juanpere N; Marta Lorenzo T; Salido M; Nonell L; David López T; Rodríguez-Vida A; Bellmunt J; Fumadó L; Cecchini L; Lloreta-Trull J
Prostate; 2021 Dec; 81(16):1267-1277. PubMed ID: 34533858
[TBL] [Abstract][Full Text] [Related]
10. SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone Sensitivity.
Boysen G; Rodrigues DN; Rescigno P; Seed G; Dolling D; Riisnaes R; Crespo M; Zafeiriou Z; Sumanasuriya S; Bianchini D; Hunt J; Moloney D; Perez-Lopez R; Tunariu N; Miranda S; Figueiredo I; Ferreira A; Christova R; Gil V; Aziz S; Bertan C; de Oliveira FM; Atkin M; Clarke M; Goodall J; Sharp A; MacDonald T; Rubin MA; Yuan W; Barbieri CE; Carreira S; Mateo J; de Bono JS
Clin Cancer Res; 2018 Nov; 24(22):5585-5593. PubMed ID: 30068710
[No Abstract] [Full Text] [Related]
11. Prostate Cancer Germline Variations and Implications for Screening and Treatment.
Dias A; Kote-Jarai Z; Mikropoulos C; Eeles R
Cold Spring Harb Perspect Med; 2018 Sep; 8(9):. PubMed ID: 29101112
[TBL] [Abstract][Full Text] [Related]
12. The Role of Genetic Polymorphisms in the Diagnosis and Management of Prostate Cancer: An Update.
Dell'atti L; Aguiari G
Anticancer Res; 2023 Jan; 43(1):317-322. PubMed ID: 36585200
[TBL] [Abstract][Full Text] [Related]
13. SPOP and FOXA1 mutations are associated with PSA recurrence in ERG wt tumors, and SPOP downregulation with ERG-rearranged prostate cancer.
Hernández-Llodrà S; Segalés L; Safont A; Juanpere N; Lorenzo M; Fumadó L; Rodríguez-Vida A; Cecchini L; Bellmunt J; Lloreta-Trull J
Prostate; 2019 Jul; 79(10):1156-1165. PubMed ID: 31090082
[TBL] [Abstract][Full Text] [Related]
14. Intraductal/ductal histology and lymphovascular invasion are associated with germline DNA-repair gene mutations in prostate cancer.
Isaacsson Velho P; Silberstein JL; Markowski MC; Luo J; Lotan TL; Isaacs WB; Antonarakis ES
Prostate; 2018 Apr; 78(5):401-407. PubMed ID: 29368341
[TBL] [Abstract][Full Text] [Related]
15. Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide.
Antonarakis ES; Lu C; Luber B; Liang C; Wang H; Chen Y; Silberstein JL; Piana D; Lai Z; Chen Y; Isaacs WB; Luo J
Eur Urol; 2018 Aug; 74(2):218-225. PubMed ID: 29439820
[TBL] [Abstract][Full Text] [Related]
16. Germline Mutations and Polymorphisms of Androgen Receptor in Prostate Cancer Patients: Frequency and Results of in Silico Analysis.
Sribudiani Y; Marwan DW; Aulanni’am A; Widodo MA; Purnomo BB; Panigoro R; Utomo AB
Asian Pac J Cancer Prev; 2018 Aug; 19(8):2241-2245. PubMed ID: 30139231
[TBL] [Abstract][Full Text] [Related]
17. Germline pathogenic variants in unselected Korean men with prostate cancer.
So MK; Ahn HK; Huh J; Kim KH
Investig Clin Urol; 2022 May; 63(3):294-300. PubMed ID: 35534218
[TBL] [Abstract][Full Text] [Related]
18. Germline mutations in PPFIBP2 are associated with lethal prostate cancer.
Wu Y; Yu H; Zheng SL; Feng B; Kapron AL; Na R; Boyle JL; Shah S; Shi Z; Ewing CM; Wiley KE; Luo J; Walsh PC; Carter HB; Helfand BT; Cooney KA; Xu J; Isaacs WB
Prostate; 2018 Dec; 78(16):1222-1228. PubMed ID: 30043417
[TBL] [Abstract][Full Text] [Related]
19. Initial Findings from a High Genetic Risk Prostate Cancer Clinic.
Sessine MS; Das S; Park B; Salami SS; Kaffenberger SD; Kasputis A; Solorzano M; Luke M; Vince RA; Kaye DR; Borza T; Stoffel EM; Cobain E; Merajver SD; Jacobs MF; Milliron KJ; Caba L; van Neste L; Mondul AM; Morgan TM
Urology; 2021 Oct; 156():96-103. PubMed ID: 34280438
[TBL] [Abstract][Full Text] [Related]
20. Integrating germline and somatic variation information using genomic data for the discovery of biomarkers in prostate cancer.
Mamidi TKK; Wu J; Hicks C
BMC Cancer; 2019 Mar; 19(1):229. PubMed ID: 30871495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
